AC Immune Net Income 2016-2021 | ACIU

AC Immune net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
AC Immune Annual Net Income
(Millions of US $)
2020 $-66
2019 $46
2018 $-52
2017 $-27
2016 $-7
2015 $21
AC Immune Quarterly Net Income
(Millions of US $)
2021-06-30 $-21
2021-03-31 $-18
2020-12-31 $-21
2020-09-30 $-21
2020-06-30 $-16
2020-03-31 $-8
2019-12-31 $-20
2019-09-30 $18
2019-06-30 $-17
2019-03-31 $64
2018-12-31 $-15
2018-09-30 $-14
2018-06-30 $-11
2018-03-31 $-12
2017-12-31 $4
2017-09-30 $-9
2017-06-30 $-13
2017-03-31 $-9
2016-09-30 $-9
2016-06-30
2016-03-31 $-6
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.440B $0.016B
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48